William Winkelman, MD
Urogynecology and Reconstructive Pelvic Surgery · Cambridge, MANPI 1316289440
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,848 of the $15,538 with a category attached, or 69.8%. It is spread thinly across 17 manufacturers, the largest accounting for just 20.9%. Reporting peaked in 2024 at $4,229 and has fallen 72.5% since, to $1,161 in 2025.
Across 251 payments — averaging $61.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Coloplast$3K
- AbbVie$2K
- Intuitive Surgical$2K
- Boston Scientific$1K
- Axonics, Inc.$1K
- plus $3K from 11 others
Across 1 payment — averaging $4042.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$4K
What the payments were for
- Consulting fees$2502%
- Travel & lodging$2,98919%
- Food & beverage$10,84870%
- Education$1,2838%
- Gifts$1561%
- Entertainment$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 49 | $3,247 |
| Coloplast | 30 | $3,169 |
| AbbVie(2 entities) | 60 | $1,891 |
| Intuitive Surgical | 6 | $1,706 |
| Boston Scientific | 15 | $1,365 |
| Axonics, Inc. | 19 | $1,300 |
| Caldera Medical, Inc | 18 | $1,140 |
| Astellas Pharma US Inc | 15 | $348 |
| Sumitomo Pharma America, Inc. | 8 | $306 |
| Hologic Sales And Service, LLC | 1 | $250 |
| Pfizer | 13 | $219 |
| Laborie Medical Technologies Corp. | 3 | $195 |
| Urovant Sciences Inc | 7 | $139 |
| Gynesonics, Inc. | 1 | $105 |
| Applied Medical Resources Corporation | 3 | $88 |
| Convatec Inc. | 2 | $58 |
| Therapeuticsmd, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,658
- INTERSTIM$1,526
- ALTIS$1,126
- Axonics$1,021
- Bulkamid$673
- Desara$644
- BOTOX$468
- UPSYLON$280
- Advantage System$159
- Solyx SIS System$144
- Saffron$117
- SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM$105
How this compares
$15,538 in reported general payments places this provider in the 85th percentile of 35 urogynecology and reconstructive pelvic surgery providers in Massachusetts.
See all urogynecology and reconstructive pelvic surgery providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 183 | $125,506 |
| MyrbetriqMirabegron | 141 | $91,428 |
| Mirabegron ErMirabegron | 49 | $26,404 |
| EstringEstradiol | 38 | $19,481 |
| Estradiol | 181 | $13,946 |
| PremarinEstrogens, Conjugated | 17 | $7,148 |
| YuvafemEstradiol | 36 | $5,742 |
| Methenamine Hippurate | 15 | $1,013 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 54 | $727 |
| Trimethoprim | 12 | $674 |
| Betamethasone Dipropionate | 14 | $258 |
| Clobetasol Propionate | 15 | $245 |
| NitrofurantoinNitrofurantoin Macrocrystal | 23 | $213 |
| Gabapentin | 16 | $111 |
| Fluconazole | 17 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $306 | $125,506183 claims |
| Astellas Pharma US IncMyrbetriq | $348 | $91,428141 claims |
| PfizerEstring, Premarin | $219 | $26,62955 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 urogynecology and reconstructive pelvic surgery providers in Massachusetts.
Other urogynecology and reconstructive pelvic surgery in Cambridge
- Peter RosenblattCambridge$223K
- Eman ElkadryCambridge$130K
- Ravi PatelCambridge$7K
- Diego IllanesMilford$277K
- Amos AdelowoWorcester$30K
- Lori JonesBoston$22K
- Vikas MerchiaBrockton$15K
- John Al JamalBoston$15K
- Youngwu KimBoston$14K
- Jyot SainiWellesley$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.